Shopping Cart

Your shopping cart is currently empty

Deracoxib

Name: Deracoxib
Brand: TargetMol
SKU: T0484
Price: 29 USD
Availability: InStock
Rating: 5 (10 reviews)

Copy Product Info

😃Good

Catalog No. T0484Cas No. 169590-41-4

Alias SC 59046, SC 46, SC 046

Deracoxib (SC 46) is a non-steroidal, non-narcotic anti-inflammatory drug. It is also a selective cyclooxygenase-2 inhibitor, and IC50 Value: 70 to 150 μM(inhibition of 3 osteosarcoma cell lines).

Deracoxib

Copy Product Info

😃Good

Purity: 99.81%

Catalog No. T0484Alias SC 59046, SC 46, SC 046Cas No. 169590-41-4

Deracoxib (SC 46) is a non-steroidal, non-narcotic anti-inflammatory drug. It is also a selective cyclooxygenase-2 inhibitor, and IC50 Value: 70 to 150 μM(inhibition of 3 osteosarcoma cell lines).

Pack Size	Price	USA Warehouse	Global Warehouse
50 mg	$30	In Stock	In Stock
100 mg	$44	In Stock	In Stock
500 mg	$116	In Stock	In Stock
1 g	$163	-	In Stock
1 mL x 10 mM (in DMSO)	$29	In Stock	In Stock

Add to Cart

Add to Quotation

In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Questions

Batch Information

Select Batch

Purity:99.81%

Appearance:Solid

Color:White

Resource Download

COA HNMR LCMS

Product Introduction

Deracoxib AI Summary

Deracoxib is a multifunctional inhibitor with diverse biological activities. It strongly inhibits human Prostaglandin G/H synthase 2 (COX-2) with an IC50 of 50.12 nM and shows activity against human recombinant COX-2 with an IC50 of 50.0 nM. It also inhibits human COX-1 with a higher IC50 of 36,000 nM. In canine models, it inhibits prostaglandin G/H synthase 1 with an IC50 of 23,000 nM and COX-2 with an IC50 of 630 nM, yielding a COX-1/COX-2 selectivity ratio of 36.5. In rat models, Deracoxib demonstrated effective anti-inflammatory and analgesic properties, with ED50 values of 0.05 mg.kg-1 in the adjuvant-induced arthritis assay, 18.6 mg.kg-1 in the carrageenan-induced foot pad edema assay, and 33.0 mg.kg-1 in the carrageenan-induced hyperalgesia assay. Notably, it caused no ulceration at a dose of 200 mg/kg and had a plasma half-life of 3.5 hours following intravenous administration. The compound also inhibits Aldehyde Dehydrogenase 1 (ALDH1A1) with a potency of 39.81 μM and exhibits potent antiviral activity, including inhibition of Ebola Virus entry and SARS-CoV-2 induced cytotoxicity in multiple cell lines. It effectively blocks fluorescence uptake in OATP1B3- and OATP1B1-transfected CHO cells, indicating high transporter inhibitory potential. Additionally, Deracoxib shows a LogD7.4 value of 2.8 and a plasma protein binding (PPB) of 97.32%. It inhibits the BSEP with an IC50 of 20,180 nM, and its antiviral properties extend to inhibiting SARS-CoV-2 induced cytotoxicity, exhibiting modest effects on viral 3CL-Pro protease activity, and showing promising inhibition percentages against SARS-CoV-2 in various assays. Finally, Deracoxib also displays modest inhibitory activity on the human HDAC6 enzyme with minor variability depending on the substrate used..

Note: Summary generated by AI. Data source: ChEMBL

Bioactivity

Description	Deracoxib (SC 46) is a non-steroidal, non-narcotic anti-inflammatory drug. It is also a selective cyclooxygenase-2 inhibitor, and IC50 Value: 70 to 150 μM(inhibition of 3 osteosarcoma cell lines).
Targets&IC50	COX-2:70-150 μM
Synonyms	SC 59046, SC 46, SC 046

Chemical Properties

Molecular Weight	397.37
Formula	C₁₇H₁₄F₃N₃O₃S
Cas No.	169590-41-4
Smiles	COc1ccc(cc1F)-c1cc(nn1-c1ccc(cc1)S(N)(=O)=O)C(F)F
Relative Density.	1.48 g/cm3

Storage & Solubility Information

Storage

Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 60 mg/mL (150.99 mM), Sonication is recommended.

In Vivo Formulation

10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (5.03 mM), Sonication is recommended.

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Solution Preparation Table

DMSO

	1mg	5mg	10mg	50mg
1 mM	2.5165 mL	12.5827 mL	25.1655 mL	125.8273 mL
5 mM	0.5033 mL	2.5165 mL	5.0331 mL	25.1655 mL
10 mM	0.2517 mL	1.2583 mL	2.5165 mL	12.5827 mL
20 mM	0.1258 mL	0.6291 mL	1.2583 mL	6.2914 mL
50 mM	0.0503 mL	0.2517 mL	0.5033 mL	2.5165 mL
100 mM	0.0252 mL	0.1258 mL	0.2517 mL	1.2583 mL

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc